J&J booster dose increased antibodies in early stage studies

Aug. 25, 2021

A booster dose of Johnson & Johnson's COVID-19 vaccine generated "a rapid and robust increase in spike-binding antibodies" according to interim data from two early-stage trials.

According to J&J, a second dose of the J&J single-dose vaccine resulted in binding antibody levels nine times higher than the levels 28 days after people received their first dose. The data comes from two phase 2 studies conducted in the United States and Europe. Approximately 2,000 people in the studies got booster doses six months after their first doses of J&J's Janssen vaccine.

The study summaries are being submitted to the preprint server MedRxiv in advance of peer review.

J&J says it plans to submit the data to the FDA. The drugmaker's vaccine was absent from the government’s initial booster plan for Pfizer and Moderna, announced last week.

Read the press release